MRNA-based influenza vaccine expands breadth of B cell response in humans.

ABSTRACT: Eliciting broad and durable antibody responses against rapidly evolving pathogens like influenza viruses remains a formidable challenge^1,2. The germinal center (GC) reaction enables the immune system to generate broad, high-affinity, and durable antibody responses to vaccination^3-5. mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines induce persistent GC B cell responses in humans^6-9. Whether an mRNA-based influenza vaccine could induce a superior GC response in humans compared to the conventional inactivated influenza virus vaccine remains unclear. We assessed B cell responses in peripheral blood and draining lymph nodes in cohorts receiving the inactivated or mRNA-based quadrivalent seasonal influenza vaccine. Participants rec

SUBMITTER: Matz HC 

PROVIDER: S-EPMC11483064 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature